Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
Mult Scler
; 28(7): 1126-1130, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1861989
ABSTRACT
BACKGROUND:
Despite impressive efficacy in immunocompetent individuals, the immunogenicity of a single dose of COVID-19 vaccine in B-cell-deplete patients remains unknown.OBJECTIVES:
We aimed to quantify real-world vaccine immunogenicity in ocrelizumab recipients.METHODS:
We measured post-vaccination SARS-COV-2 immunoglobulin G (IgG) in ocrelizumab recipients using a highly sensitive Luminex assay.RESULTS:
44.1% of patients had detectable SARS-COV-2-IgG 21+ days after one vaccine dose, regardless of vaccine type (AZD1222 vs BNT162b2, odds ratio (OR) = 0.62, 95% confidence interval (CI) = 0.157-2.32, p = 0.72). B-cell count strongly predicted seroconversion (ß1 = 12.38, 95% CI = 4.59-20.16, p = 0.0029), but undetectable B-cells did not preclude it. The second vaccine seroconverted 53% of the patients who had not already responded to dose 1.CONCLUSION:
Humoral response after one COVID-19 vaccine dose is lower than expected in CD20-deplete patients.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Multiple Sclerosis, Relapsing-Remitting
/
COVID-19
/
Multiple Sclerosis
Type of study:
Prognostic study
Topics:
Vaccines
/
Variants
Limits:
Humans
Language:
English
Journal:
Mult Scler
Journal subject:
Neurology
Year:
2022
Document Type:
Article
Affiliation country:
13524585211046786
Similar
MEDLINE
...
LILACS
LIS